Biomerica Inc (BMRA) stock
BMRANasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends May 31
Số liệu tài chính tới Q1 năm tài chính 2027, quý kết thúc ngày Aug 31, 2026Last filing: 10-Q on Oct 15, 2026Score 8/3055% below fair value
$1.09−0.15 (-11.74%)
Close on Nov 18, 2026Market cap $5.01MP/E –Yield –
Biomerica operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Biomerica's operating cash flow for the twelve months ending Aug 31, 2026 was -$3.96M. For fiscal 2026 it was -$3.42M. The highest annual figure on record is $1.39M in fiscal 2013.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2026 | May 31, 2026 | -$3.42M | – |
| FY2025 | May 31, 2025 | -$3.84M | – |
| FY2024 | May 31, 2024 | -$5.36M | – |
| FY2023 | May 31, 2023 | -$5.47M | – |
| FY2022 | May 31, 2022 | -$479.00K | – |
| FY2021 | May 31, 2021 | -$5.25M | – |
| FY2020 | May 31, 2020 | -$4.30M | – |
| FY2019 | May 31, 2019 | -$2.24M | – |
| FY2018 | May 31, 2018 | -$1.17M | – |
| FY2017 | May 31, 2017 | -$722.86K | – |
| FY2016 | May 31, 2016 | -$208.78K | – |
| FY2015 | May 31, 2015 | -$405.48K | – |
| FY2014 | May 31, 2014 | -$862.27K | -161.9% |
| FY2013 | May 31, 2013 | $1.39M | +845.7% |
| FY2012 | May 31, 2012 | $147.41K | -55.2% |
| FY2011 | May 31, 2011 | $328.80K | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q1 FY2027CQ3 2026 | Aug 31, 2026 | -$802.00K | – |
| Q4 FY2026CQ2 2026 | May 31, 2026 | -$912.00K | – |
| Q3 FY2026CQ1 2026 | Feb 28, 2026 | -$1.25M | – |
| Q2 FY2026CQ4 2025 | Nov 30, 2025 | -$991.00K | – |
| Q1 FY2026CQ3 2025 | Aug 31, 2025 | -$268.00K | – |
| Q4 FY2025CQ2 2025 | May 31, 2025 | -$662.00K | – |
| Q3 FY2025CQ1 2025 | Feb 28, 2025 | -$1.05M | – |
| Q2 FY2025CQ4 2024 | Nov 30, 2024 | -$791.00K | – |
| Q1 FY2025CQ3 2024 | Aug 31, 2024 | -$1.34M | – |
| Q4 FY2024CQ2 2024 | May 31, 2024 | -$1.04M | – |
| Q3 FY2024CQ1 2024 | Feb 29, 2024 | -$1.80M | – |
| Q2 FY2024CQ4 2023 | Nov 30, 2023 | -$842.00K | – |
| Q1 FY2024CQ3 2023 | Aug 31, 2023 | -$1.67M | – |
| Q4 FY2023CQ2 2023 | May 31, 2023 | -$963.00K | – |
| Q3 FY2023CQ1 2023 | Feb 28, 2023 | -$1.73M | -173.1% |
| Q2 FY2023CQ4 2022 | Nov 30, 2022 | -$1.21M | -190.3% |
| Q1 FY2023CQ3 2022 | Aug 31, 2022 | -$1.57M | -2174.2% |
| Q4 FY2022CQ2 2022 | May 31, 2022 | -$4.26M | – |
| Q3 FY2022CQ1 2022 | Feb 28, 2022 | $2.36M | – |
| Q2 FY2022CQ4 2021 | Nov 30, 2021 | $1.34M | – |
| Q1 FY2022CQ3 2021 | Aug 31, 2021 | $75.84K | – |
| Q4 FY2021CQ2 2021 | May 31, 2021 | -$1.01M | – |
| Q3 FY2021CQ1 2021 | Feb 28, 2021 | -$1.36M | – |
| Q2 FY2021CQ4 2020 | Nov 30, 2020 | -$1.28M | – |
| Q1 FY2021CQ3 2020 | Aug 31, 2020 | -$1.60M | – |
| Q4 FY2020CQ2 2020 | May 31, 2020 | -$3.49M | – |
| Q3 FY2020CQ1 2020 | Feb 29, 2020 | -$436.92K | – |
| Q2 FY2020CQ4 2019 | Nov 30, 2019 | -$357.84K | – |
| Q1 FY2020CQ3 2019 | Aug 31, 2019 | -$8.15K | – |
| Q4 FY2019CQ2 2019 | May 31, 2019 | -$986.33K | – |
| Q3 FY2019CQ1 2019 | Feb 28, 2019 | -$256.64K | – |
| Q2 FY2019CQ4 2018 | Nov 30, 2018 | -$244.41K | – |
| Q1 FY2019CQ3 2018 | Aug 31, 2018 | -$756.66K | – |
| Q4 FY2018CQ2 2018 | May 31, 2018 | -$322.05K | – |
| Q3 FY2018CQ1 2018 | Feb 28, 2018 | -$488.82K | – |
| Q2 FY2018CQ4 2017 | Nov 30, 2017 | -$238.64K | – |
| Q1 FY2018CQ3 2017 | Aug 31, 2017 | -$124.71K | – |
| Q4 FY2017CQ2 2017 | May 31, 2017 | -$333.48K | – |
| Q3 FY2017CQ1 2017 | Feb 28, 2017 | -$81.49K | – |
| Q2 FY2017CQ4 2016 | Nov 30, 2016 | -$235.96K | – |
See a number that looks wrong?